134,108 Shares in MyoKardia, Inc. (NASDAQ:MYOK) Acquired by OxFORD Asset Management LLP

OxFORD Asset Management LLP acquired a new position in shares of MyoKardia, Inc. (NASDAQ:MYOK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 134,108 shares of the biotechnology company’s stock, valued at approximately $1,757,000. OxFORD Asset Management LLP owned about 0.43% of MyoKardia at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Wellington Management Group LLP boosted its holdings in MyoKardia by 12.5% during the 1st quarter. Wellington Management Group LLP now owns 3,154,734 shares of the biotechnology company’s stock worth $41,485,000 after acquiring an additional 349,768 shares during the last quarter. Vanguard Group Inc. boosted its holdings in MyoKardia by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after acquiring an additional 78,800 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in MyoKardia by 103.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after acquiring an additional 242,408 shares during the last quarter. Northern Trust Corp boosted its holdings in MyoKardia by 31.9% during the 2nd quarter. Northern Trust Corp now owns 202,983 shares of the biotechnology company’s stock worth $2,658,000 after acquiring an additional 49,044 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its holdings in MyoKardia by 28.0% during the 2nd quarter. Marshall Wace North America L.P. now owns 155,274 shares of the biotechnology company’s stock worth $2,019,000 after acquiring an additional 33,970 shares during the last quarter. 42.94% of the stock is currently owned by hedge funds and other institutional investors.

MYOK has been the topic of a number of analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 price objective (up from $32.00) on shares of MyoKardia in a report on Tuesday, August 8th. TheStreet raised shares of MyoKardia from a “d+” rating to a “c” rating in a report on Thursday, July 6th. Zacks Investment Research raised shares of MyoKardia from a “sell” rating to a “hold” rating in a report on Tuesday. ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Finally, Cowen and Company boosted their price target on shares of MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a report on Monday, August 7th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. MyoKardia has a consensus rating of “Buy” and a consensus target price of $55.00.

In related news, insider Anastasios Gianakakos sold 32,988 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $15.00, for a total value of $494,820.00. Following the completion of the sale, the insider now owns 541,151 shares of the company’s stock, valued at $8,117,265. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Kevin P. Starr sold 75,313 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $40.28, for a total value of $3,033,607.64. The disclosure for this sale can be found here. Insiders have sold 1,786,501 shares of company stock valued at $74,371,815 in the last three months. Insiders own 33.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “134,108 Shares in MyoKardia, Inc. (NASDAQ:MYOK) Acquired by OxFORD Asset Management LLP” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/134108-shares-in-myokardia-inc-myok-acquired-by-oxford-asset-management-llp/1701527.html.

MyoKardia, Inc. (NASDAQ:MYOK) opened at 37.10 on Wednesday. The company’s market capitalization is $1.17 billion. MyoKardia, Inc. has a 52-week low of $10.55 and a 52-week high of $49.55. The company has a 50 day moving average of $43.13 and a 200 day moving average of $43.13.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The firm had revenue of $5.60 million for the quarter, compared to analyst estimates of $6.73 million. During the same period in the previous year, the company earned ($0.37) EPS. MyoKardia’s revenue was up 60.0% compared to the same quarter last year. On average, equities research analysts forecast that MyoKardia, Inc. will post ($1.63) earnings per share for the current fiscal year.

MyoKardia Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.